95 related articles for article (PubMed ID: 16455473)
1. Immunomodulatory effects of non-steroidal anti-inflammatory drugs in Barrett's oesophagus.
Rajendra S
Lancet Oncol; 2006 Feb; 7(2):103-4. PubMed ID: 16455473
[No Abstract] [Full Text] [Related]
2. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma.
Tsibouris P; Hendrickse MT; Isaacs PE
Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913
[TBL] [Abstract][Full Text] [Related]
3. Molecular biology of Barrett's cancer.
Atherfold PA; Jankowski JA
Best Pract Res Clin Gastroenterol; 2006; 20(5):813-27. PubMed ID: 16997163
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers in Barrett's esophagus (review).
van Lieshout EM; Jansen JB; Peters WH
Int J Oncol; 1998 Oct; 13(4):855-64. PubMed ID: 9735417
[TBL] [Abstract][Full Text] [Related]
5. Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.
Chemnitzer O; Götzel K; Maurer L; Dietrich A; Eichfeld U; Lyros O; Jansen-Winkeln B; Hoffmeister A; Gockel I; Thieme R
Dig Dis Sci; 2017 Dec; 62(12):3391-3401. PubMed ID: 29086334
[TBL] [Abstract][Full Text] [Related]
6. Barrett's oesophagus and oesophageal adenocarcinoma: how does acid interfere with cell proliferation and differentiation?
Fitzgerald RC
Gut; 2005 Mar; 54 Suppl 1(Suppl 1):i21-6. PubMed ID: 15711004
[TBL] [Abstract][Full Text] [Related]
7. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
[TBL] [Abstract][Full Text] [Related]
8. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
9. Acidic fibroblast growth factor is expressed sequentially in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Soslow RA; Petersen CG; Remotti H; Altorki N
Dis Esophagus; 2001; 14(1):23-7. PubMed ID: 11422301
[TBL] [Abstract][Full Text] [Related]
10. Correspondence re: R. Kim et al., Etiology of Barrett's metaplasia and esophageal adenocarcinoma. Cancer Epidemiol., Biomark. Prev., 6: 369-377, 1997.
Morgan G
Cancer Epidemiol Biomarkers Prev; 1998 Mar; 7(3):265. PubMed ID: 9521445
[No Abstract] [Full Text] [Related]
11. Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study.
Vaughan TL; Dong LM; Blount PL; Ayub K; Odze RD; Sanchez CA; Rabinovitch PS; Reid BJ
Lancet Oncol; 2005 Dec; 6(12):945-52. PubMed ID: 16321762
[TBL] [Abstract][Full Text] [Related]
12. Sex hormone receptor immunohistochemistry staining in Barrett's oesophagus and adenocarcinoma.
Tiffin N; Suvarna SK; Trudgill NJ; Riley SA
Histopathology; 2003 Jan; 42(1):95-6. PubMed ID: 12493034
[No Abstract] [Full Text] [Related]
13. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma.
Morita S; Matsumoto Y; Okuyama S; Ono K; Kitamura Y; Tomori A; Oyama T; Amano Y; Kinoshita Y; Chiba T; Marusawa H
Carcinogenesis; 2011 Nov; 32(11):1706-12. PubMed ID: 21890457
[TBL] [Abstract][Full Text] [Related]
14. [Barrett esophagus: current state of the problem].
Belova GV; Sokolov VV; Budzinskiĭ AA; Mel'chenko DS
Eksp Klin Gastroenterol; 2007; (3):36-44. PubMed ID: 17937004
[No Abstract] [Full Text] [Related]
15. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Morales CP; Lee EL; Shay JW
Cancer; 1998 Aug; 83(4):652-9. PubMed ID: 9708927
[TBL] [Abstract][Full Text] [Related]
16. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
[TBL] [Abstract][Full Text] [Related]
17. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
18. Ablation of Barrett's oesophagus: towards improved outcomes for oesophageal cancer?
Mayne GC; Bright T; Hussey DJ; Watson DI
ANZ J Surg; 2012 Sep; 82(9):592-8. PubMed ID: 22901306
[TBL] [Abstract][Full Text] [Related]
19. Controversies of the cardiac mucosa and Barrett's oesophagus.
Lombard C
Histopathology; 2006 Jul; 49(1):97-8; author reply 98. PubMed ID: 16842257
[No Abstract] [Full Text] [Related]
20. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
